Press briefing 3 Gastrointestinal and Genitourinary cancers
Moderator and Commentator LBA12_PR and LBA14_PR: Ignacio Duran, Spain
Commentator LBA10_PR: Angela Lamarca, UK
Link to press releases and abstracts
- LBA10_PR - ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
Ghassan Abou-Alfa, US - LBA12_PR - PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Maha Hussain, US - LBA14_PR - IMvigor130: efficacy and safety from a Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
Enrique Grande, Spain - New Results from JAVELIN Renal 101 at the bottom of the page
New Results from JAVELIN Renal 101:
A year ago at the ESMO 2018 press briefing the JAVELIN Renal 101 study results were reported:
Now at ESMO 2019 new data about JAVELIN renal 101 were reported:
Conclusions: Pts with sRCC who received A + Ax had PFS and ORR benefit over S, supporting the results in the overall trial population. This analysis provides insight into the biology of an aggressive subtype of RCC and suggests a potential new treatment option.
Conclusions A + Ax resulted in greater shrinkage of the primary renal tumour vs S in pts with aRCC who did not undergo uCN. This is the first report of the efficacy of immuno-oncology + tyrosine kinase inhibitor therapy on the primary tumour in the context of metastatic RCC and provides insight into future neoadjuvant strategies in aRCC.